Literature DB >> 9499044

Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates.

T M Ross1, P D Bieniasz, B R Cullen.   

Abstract

Infection of CD4-positive cells by human immunodeficiency virus type 1 (HIV-1) requires functional interaction of the viral envelope protein with a coreceptor belonging to the chemokine receptor family of seven-membrane-spanning receptors. For the majority of macrophage-tropic HIV-1 isolates, the physiologically relevant coreceptor is the human CCR-5 (hCCR-5) receptor. Although the murine homolog of CCR-5 (mCCR-5) is unable to mediate HIV-1 infection, chimeric hCCR-5/mCCR-5 molecules containing single extracellular domains derived from hCCR-5 are effective coreceptors for certain macrophage-tropic HIV-1 isolates. Here, we have sought to identify residues in hCCR-5 critical for HIV-1 infection by substitution of mCCR-5-derived residues into the context of functional chimeric hCCR-5/mCCR-5 receptor molecules. Using this strategy, we demonstrate that residues 7, 13, and 15 in the first extracellular domain and residue 180 in the third extracellular domain of CCR-5 are important for HIV-1 envelope-mediated membrane fusion. Of interest, certain substitutions, for example, at residues 184 and 185 in the third extracellular domain, have no phenotype when introduced individually but strongly inhibit hCCR-5 coreceptor function when present together. We hypothesize that these changes, which do not preclude chemokine receptor function, may inhibit a conformational transition in hCCR-5 that contributes to HIV-1 infection. Finally, we report that substitution of glycine for valine at residue 5 in CCR-5 can significantly enhance the level of envelope-dependent cell fusion by expressing cells. The diversity of the mutant phenotypes observed in this mutational analysis, combined with their wide distribution across the extracellular regions of CCR-5, emphasizes the complexity of the interaction between HIV-1 envelope and coreceptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499044      PMCID: PMC109483          DOI: 10.1128/JVI.72.3.1918-1924.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

2.  Expression cloning of new receptors used by simian and human immunodeficiency viruses.

Authors:  H K Deng; D Unutmaz; V N KewalRamani; D R Littman
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

3.  A new SIV co-receptor, STRL33.

Authors:  G Alkhatib; F Liao; E A Berger; J M Farber; K W Peden
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

4.  Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

Authors:  R E Atchison; J Gosling; F S Monteclaro; C Franci; L Digilio; I F Charo; M A Goldsmith
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

5.  Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.

Authors:  L Picard; G Simmons; C A Power; A Meyer; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 6.  Co-receptors for HIV-1 entry.

Authors:  J P Moore; A Trkola; T Dragic
Journal:  Curr Opin Immunol       Date:  1997-08       Impact factor: 7.486

7.  Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop.

Authors:  R F Speck; K Wehrly; E J Platt; R E Atchison; I F Charo; D Kabat; B Chesebro; M A Goldsmith
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.

Authors:  B J Doranz; Z H Lu; J Rucker; T Y Zhang; M Sharron; Y H Cen; Z X Wang; H H Guo; J G Du; M A Accavitti; R W Doms; S C Peiper
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  Cloning and characterization of a novel murine macrophage inflammatory protein-1 alpha receptor.

Authors:  A Meyer; A J Coyle; A E Proudfoot; T N Wells; C A Power
Journal:  J Biol Chem       Date:  1996-06-14       Impact factor: 5.157

10.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

View more
  27 in total

1.  Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.

Authors:  T L Hoffman; C C LaBranche; W Zhang; G Canziani; J Robinson; I Chaiken; J A Hoxie; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Authors:  Cajetan Dogo-Isonagie; Son Lam; Elena Gustchina; Priyamvada Acharya; Yongping Yang; Syed Shahzad-ul-Hussan; G Marius Clore; Peter D Kwong; Carole A Bewley
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

4.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.

Authors:  K E Follis; M Trahey; R A LaCasse; J H Nunberg
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.

Authors:  Jun Zhang; Eileen Rao; Marianna Dioszegi; Rama Kondru; Andre DeRosier; Eva Chan; Stephan Schwoerer; Nick Cammack; Michael Brandt; Surya Sankuratri; Changhua Ji
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

7.  Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

Authors:  B Chackerian; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

8.  Human CRM1 augments production of infectious human and feline immunodeficiency viruses from murine cells.

Authors:  Hila Elinav; Yuanfei Wu; Ayse Coskun; Katarzyna Hryckiewicz; Iris Kemler; Yani Hu; Hilary Rogers; Bing Hao; Choukri Ben Mamoun; Eric Poeschla; Richard Sutton
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

9.  Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.

Authors:  Christoph Seibert; Martine Cadene; Anthony Sanfiz; Brian T Chait; Thomas P Sakmar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

10.  CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains.

Authors:  S Genoud; F Kajumo; Y Guo; D Thompson; T Dragic
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.